Choice of an Optimal Modular Strategy for the Synthesis of DOTA-Containing Heterobivalent Agents Targeting PSMA and GRPr
Heterodimeric approaches have emerged as a promising method for simultaneously targeting multiple receptors on tumor cells using a single molecule. Simultaneous targeting of the prostate-specific membrane antigen (PSMA) and the gastrin-releasing peptide receptor (GRPr) holds the potential to improve...
Saved in:
Published in | Bioconjugate chemistry Vol. 36; no. 4; pp. 748 - 761 |
---|---|
Main Authors | , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Chemical Society
16.04.2025
|
Subjects | |
Online Access | Get full text |
ISSN | 1043-1802 1520-4812 1520-4812 |
DOI | 10.1021/acs.bioconjchem.5c00033 |
Cover
Loading…
Abstract | Heterodimeric approaches have emerged as a promising method for simultaneously targeting multiple receptors on tumor cells using a single molecule. Simultaneous targeting of the prostate-specific membrane antigen (PSMA) and the gastrin-releasing peptide receptor (GRPr) holds the potential to improve the accuracy of prostate cancer diagnosis. The aim of this study was to develop a convenient and simple modular strategy for the creation of heterobivalent (HBV) conjugates targeting PSMA/GRPr receptors. For this purpose, we developed and compared six alternative routes for the stereoselective synthesis of HBV conjugates designed to deliver the chelating agent DOTA to PSMA/GRPr receptors. The comparison of these alternative synthetic pathways took into account such factors as efficiency, complexity, synthesis, and purification details, as well as yields of the target compounds. Optimal conditions for the stereoselective synthesis of HBV ligands to PSMA and GRPr, which could serve as molecular platforms for the targeted delivery of therapeutic or diagnostic agents to these receptors, were revealed. For synthesized HBV ligand 26 x and its HBV conjugate with DOTA 27, the complete signal assignment in 1H, 13C, and 15N NMR spectra was achieved using 2D NMR techniques. Based on these data, comprehensive signal assignments were provided for all final compounds in their NMR spectra. The final HBV conjugate 27 was labeled with Lu-177, with yields >99%, and the obtained radiotracer was studied in vitro for its binding specificity, with determining of the K D and B max using LNCaP (PSMA+) and PC-3 (GRPr+) cell lines. |
---|---|
AbstractList | Heterodimeric approaches have emerged as a promising method for simultaneously targeting multiple receptors on tumor cells using a single molecule. Simultaneous targeting of the prostate-specific membrane antigen (PSMA) and the gastrin-releasing peptide receptor (GRPr) holds the potential to improve the accuracy of prostate cancer diagnosis. The aim of this study was to develop a convenient and simple modular strategy for the creation of heterobivalent (HBV) conjugates targeting PSMA/GRPr receptors. For this purpose, we developed and compared six alternative routes for the stereoselective synthesis of HBV conjugates designed to deliver the chelating agent DOTA to PSMA/GRPr receptors. The comparison of these alternative synthetic pathways took into account such factors as efficiency, complexity, synthesis, and purification details, as well as yields of the target compounds. Optimal conditions for the stereoselective synthesis of HBV ligands to PSMA and GRPr, which could serve as molecular platforms for the targeted delivery of therapeutic or diagnostic agents to these receptors, were revealed. For synthesized HBV ligand 26 x and its HBV conjugate with DOTA 27, the complete signal assignment in 1H, 13C, and 15N NMR spectra was achieved using 2D NMR techniques. Based on these data, comprehensive signal assignments were provided for all final compounds in their NMR spectra. The final HBV conjugate 27 was labeled with Lu-177, with yields >99%, and the obtained radiotracer was studied in vitro for its binding specificity, with determining of the K D and B max using LNCaP (PSMA+) and PC-3 (GRPr+) cell lines. Heterodimeric approaches have emerged as a promising method for simultaneously targeting multiple receptors on tumor cells using a single molecule. Simultaneous targeting of the prostate-specific membrane antigen (PSMA) and the gastrin-releasing peptide receptor (GRPr) holds the potential to improve the accuracy of prostate cancer diagnosis. The aim of this study was to develop a convenient and simple modular strategy for the creation of heterobivalent (HBV) conjugates targeting PSMA/GRPr receptors. For this purpose, we developed and compared six alternative routes for the stereoselective synthesis of HBV conjugates designed to deliver the chelating agent DOTA to PSMA/GRPr receptors. The comparison of these alternative synthetic pathways took into account such factors as efficiency, complexity, synthesis, and purification details, as well as yields of the target compounds. Optimal conditions for the stereoselective synthesis of HBV ligands to PSMA and GRPr, which could serve as molecular platforms for the targeted delivery of therapeutic or diagnostic agents to these receptors, were revealed. For synthesized HBV ligand 26x and its HBV conjugate with DOTA 27, the complete signal assignment in 1H, 13C, and 15N NMR spectra was achieved using 2D NMR techniques. Based on these data, comprehensive signal assignments were provided for all final compounds in their NMR spectra. The final HBV conjugate 27 was labeled with Lu-177, with yields >99%, and the obtained radiotracer was studied in vitro for its binding specificity, with determining of the KD and Bmax using LNCaP (PSMA+) and PC-3 (GRPr+) cell lines. Heterodimeric approaches have emerged as a promising method for simultaneously targeting multiple receptors on tumor cells using a single molecule. Simultaneous targeting of the prostate-specific membrane antigen (PSMA) and the gastrin-releasing peptide receptor (GRPr) holds the potential to improve the accuracy of prostate cancer diagnosis. The aim of this study was to develop a convenient and simple modular strategy for the creation of heterobivalent (HBV) conjugates targeting PSMA/GRPr receptors. For this purpose, we developed and compared six alternative routes for the stereoselective synthesis of HBV conjugates designed to deliver the chelating agent DOTA to PSMA/GRPr receptors. The comparison of these alternative synthetic pathways took into account such factors as efficiency, complexity, synthesis, and purification details, as well as yields of the target compounds. Optimal conditions for the stereoselective synthesis of HBV ligands to PSMA and GRPr, which could serve as molecular platforms for the targeted delivery of therapeutic or diagnostic agents to these receptors, were revealed. For synthesized HBV ligand 26x and its HBV conjugate with DOTA 27, the complete signal assignment in 1H, 13C, and 15N NMR spectra was achieved using 2D NMR techniques. Based on these data, comprehensive signal assignments were provided for all final compounds in their NMR spectra. The final HBV conjugate 27 was labeled with Lu-177, with yields >99%, and the obtained radiotracer was studied in vitro for its binding specificity, with determining of the KD and Bmax using LNCaP (PSMA+) and PC-3 (GRPr+) cell lines.Heterodimeric approaches have emerged as a promising method for simultaneously targeting multiple receptors on tumor cells using a single molecule. Simultaneous targeting of the prostate-specific membrane antigen (PSMA) and the gastrin-releasing peptide receptor (GRPr) holds the potential to improve the accuracy of prostate cancer diagnosis. The aim of this study was to develop a convenient and simple modular strategy for the creation of heterobivalent (HBV) conjugates targeting PSMA/GRPr receptors. For this purpose, we developed and compared six alternative routes for the stereoselective synthesis of HBV conjugates designed to deliver the chelating agent DOTA to PSMA/GRPr receptors. The comparison of these alternative synthetic pathways took into account such factors as efficiency, complexity, synthesis, and purification details, as well as yields of the target compounds. Optimal conditions for the stereoselective synthesis of HBV ligands to PSMA and GRPr, which could serve as molecular platforms for the targeted delivery of therapeutic or diagnostic agents to these receptors, were revealed. For synthesized HBV ligand 26x and its HBV conjugate with DOTA 27, the complete signal assignment in 1H, 13C, and 15N NMR spectra was achieved using 2D NMR techniques. Based on these data, comprehensive signal assignments were provided for all final compounds in their NMR spectra. The final HBV conjugate 27 was labeled with Lu-177, with yields >99%, and the obtained radiotracer was studied in vitro for its binding specificity, with determining of the KD and Bmax using LNCaP (PSMA+) and PC-3 (GRPr+) cell lines. Heterodimeric approaches have emerged as a promising method for simultaneously targeting multiple receptors on tumor cells using a single molecule. Simultaneous targeting of the prostate-specific membrane antigen (PSMA) and the gastrin-releasing peptide receptor (GRPr) holds the potential to improve the accuracy of prostate cancer diagnosis. The aim of this study was to develop a convenient and simple modular strategy for the creation of heterobivalent (HBV) conjugates targeting PSMA/GRPr receptors. For this purpose, we developed and compared six alternative routes for the stereoselective synthesis of HBV conjugates designed to deliver the chelating agent DOTA to PSMA/GRPr receptors. The comparison of these alternative synthetic pathways took into account such factors as efficiency, complexity, synthesis, and purification details, as well as yields of the target compounds. Optimal conditions for the stereoselective synthesis of HBV ligands to PSMA and GRPr, which could serve as molecular platforms for the targeted delivery of therapeutic or diagnostic agents to these receptors, were revealed. For synthesized HBV ligand and its HBV conjugate with DOTA , the complete signal assignment in H, C, and N NMR spectra was achieved using 2D NMR techniques. Based on these data, comprehensive signal assignments were provided for all final compounds in their NMR spectra. The final HBV conjugate was labeled with Lu-177, with yields >99%, and the obtained radiotracer was studied in vitro for its binding specificity, with determining of the and using LNCaP (PSMA+) and PC-3 (GRPr+) cell lines. |
Author | Larkina, Mariia S. Roznyatovsky, Vitaly A. Yusubov, Mekhman S. Machulkin, Aleksei E. Zyk, Nikolay Y. Varvashenya, Ruslan Petrova, Juliana V. Grigoriev, Gleb P. Petrov, Stanislav A. Grishin, Yuri K. Plotnikov, Evgenii Prach, Anastasia Beloglazkina, Elena K. Orlov, Grigory A. Beloglazkina, Maria A. Bodenko, Vitalina |
AuthorAffiliation | Department of Chemistry Department of Organic Chemistry People’s Friendship University of Russia Named after Patrice Lumumba (RUDN University) The Laboratory of Molecular Therapy of Cancer, Cancer Research Institute Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences Scientific and Educational Laboratory of Chemical and Pharmaceutical Research Tomsk National Research Medical Center, Russian Academy of Sciences Department of Biochemistry |
AuthorAffiliation_xml | – name: Department of Organic Chemistry – name: People’s Friendship University of Russia Named after Patrice Lumumba (RUDN University) – name: Department of Chemistry – name: Tomsk National Research Medical Center, Russian Academy of Sciences – name: The Laboratory of Molecular Therapy of Cancer, Cancer Research Institute – name: Scientific and Educational Laboratory of Chemical and Pharmaceutical Research – name: Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences – name: Department of Biochemistry |
Author_xml | – sequence: 1 givenname: Stanislav A. orcidid: 0000-0002-6000-6100 surname: Petrov fullname: Petrov, Stanislav A. email: stanislavpetrovsh1994@gmail.com organization: Department of Chemistry – sequence: 2 givenname: Gleb P. surname: Grigoriev fullname: Grigoriev, Gleb P. organization: Department of Chemistry – sequence: 3 givenname: Grigory A. surname: Orlov fullname: Orlov, Grigory A. organization: Department of Chemistry – sequence: 4 givenname: Nikolay Y. surname: Zyk fullname: Zyk, Nikolay Y. organization: Department of Chemistry – sequence: 5 givenname: Yuri K. surname: Grishin fullname: Grishin, Yuri K. organization: Department of Chemistry – sequence: 6 givenname: Vitaly A. surname: Roznyatovsky fullname: Roznyatovsky, Vitaly A. organization: Department of Chemistry – sequence: 7 givenname: Maria A. surname: Beloglazkina fullname: Beloglazkina, Maria A. organization: Department of Chemistry – sequence: 8 givenname: Juliana V. orcidid: 0000-0003-4680-5755 surname: Petrova fullname: Petrova, Juliana V. organization: People’s Friendship University of Russia Named after Patrice Lumumba (RUDN University) – sequence: 9 givenname: Aleksei E. orcidid: 0000-0001-7975-0346 surname: Machulkin fullname: Machulkin, Aleksei E. organization: People’s Friendship University of Russia Named After Patrice Lumumba (RUDN University) – sequence: 10 givenname: Mariia S. orcidid: 0000-0003-1176-2441 surname: Larkina fullname: Larkina, Mariia S. organization: Scientific and Educational Laboratory of Chemical and Pharmaceutical Research – sequence: 11 givenname: Anastasia surname: Prach fullname: Prach, Anastasia organization: Tomsk National Research Medical Center, Russian Academy of Sciences – sequence: 12 givenname: Ruslan surname: Varvashenya fullname: Varvashenya, Ruslan organization: Scientific and Educational Laboratory of Chemical and Pharmaceutical Research – sequence: 13 givenname: Vitalina surname: Bodenko fullname: Bodenko, Vitalina organization: Scientific and Educational Laboratory of Chemical and Pharmaceutical Research – sequence: 14 givenname: Evgenii surname: Plotnikov fullname: Plotnikov, Evgenii organization: Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences – sequence: 15 givenname: Mekhman S. surname: Yusubov fullname: Yusubov, Mekhman S. organization: Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences – sequence: 16 givenname: Elena K. orcidid: 0000-0001-6796-8241 surname: Beloglazkina fullname: Beloglazkina, Elena K. organization: Department of Chemistry |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40176353$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkU1vEzEQhi1URD_gL4AlLlw22B5v1nuMArRIrVKRcLa83tlko40dbC8i_76OklaIC5eZkeZ5Z0bzXpML5x0S8oGzCWeCfzY2TpreW--2doO7SWkZYwCvyBUvBSuk4uIi10xCwRUTl-Q6xm1Gaq7EG3IpGa-mUMIV-TPf-N4i9R01ji72qd-ZgT74dhxMoMsUTML1gXY-0LRBujy4nGIfj4Ivi9WsmHuXTO96t6Z3mDD4pv9tBnSJztY5RroyYY3p2H9cPszylpbe_ngMb8nrzgwR353zDfn57etqflfcL26_z2f3hQGAVABUjZW15LLtFAcL0NWiwrpWDZNobQd1qawxosSKoWxLqGopUcqpYNOmaeGGfDrN3Qf_a8SY9K6PFofBOPRj1MBVWSlVS5bRj_-gWz8Gl6_TIBgvy4orlan3Z2psdtjqfcgvCwf9_NMMVCfABh9jwO4F4Uwf3dPZPf2Xe_rsXlbCSXkEXnb_T_UEELihlA |
Cites_doi | 10.1002/pros.22789 10.1021/acsomega.4c00489 10.1021/jm020515w 10.1021/acsmedchemlett.4c00324 10.1016/S0090-4295(96)00184-7 10.1021/jm100729b 10.1097/MNM.0000000000001520 10.1002/psc.2836 10.1016/j.jscs.2010.12.006 10.1021/bc025536j 10.1016/1078-1439(95)00002-Y 10.3390/pharmaceutics11070358 10.1021/bc200279b 10.3390/cancers13225766 10.3390/molecules22040523 10.18632/oncotarget.9004 10.1021/acs.jmedchem.0c01785 10.2967/jnumed.109.064444 10.1016/j.nucmedbio.2014.01.001 10.1007/s00726-010-0546-y 10.1097/MNM.0000000000000966 10.3390/pharmaceutics12070614 10.1016/j.bmc.2004.06.031 10.1021/jm0001774 10.1039/c39940002559 10.1021/bc300659k 10.1021/acs.jmedchem.5b01268 10.1016/j.molstruc.2021.130127 10.1021/bc4005377 10.1021/jm401703a 10.1016/j.bmcl.2019.01.040 10.1021/jm300488m 10.1016/j.nucmedbio.2021.03.005 10.1021/acsmedchemlett.3c00057 10.1016/j.humpath.2006.11.012 10.1021/acs.bioconjchem.5b00687 10.2967/jnumed.114.147413 10.3390/pharmaceutics16111358 10.1016/j.bioorg.2019.103154 10.3322/caac.21492 10.1021/jm051019l 10.1021/acs.jmedchem.5b01210 10.3390/cancers11091371 10.1021/acs.bioconjchem.5b00679 10.1002/pros.22784 10.1021/acsptsci.4c00070 10.1046/j.1525-1411.2001.003001001.x 10.3390/ph16050674 10.1007/s10967-018-6285-3 10.1002/jlcr.3749 10.3390/cancers15020442 |
ContentType | Journal Article |
Copyright | 2025 American Chemical Society Copyright American Chemical Society 2025 |
Copyright_xml | – notice: 2025 American Chemical Society – notice: Copyright American Chemical Society 2025 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QO 7TM 8FD FR3 P64 7X8 |
DOI | 10.1021/acs.bioconjchem.5c00033 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Biotechnology Research Abstracts Nucleic Acids Abstracts Technology Research Database Engineering Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Engineering Research Database Biotechnology Research Abstracts Technology Research Database Nucleic Acids Abstracts Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitleList | Engineering Research Database MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Anatomy & Physiology Chemistry Biology |
EISSN | 1520-4812 |
EndPage | 761 |
ExternalDocumentID | 40176353 10_1021_acs_bioconjchem_5c00033 e96468030 |
Genre | Journal Article |
GroupedDBID | --- -~X 23N 4.4 55A 5GY 5VS 7~N AABXI ABJNI ABMVS ABQRX ABUCX ACGFS ACIWK ACJ ACPRK ACS ADHLV AEESW AENEX AFEFF AFRAH AGXLV AHGAQ ALMA_UNASSIGNED_HOLDINGS AQSVZ BAANH CS3 CUPRZ DU5 EBS ED~ F5P GGK GNL IH9 JG~ LG6 P2P PQQKQ ROL TN5 TWZ UI2 VF5 VG9 W1F XKZ YZZ AAYXX ABBLG ABLBI CITATION CGR CUY CVF ECM EIF NPM 7QO 7TM 8FD FR3 P64 7X8 |
ID | FETCH-LOGICAL-a333t-337bc49414df813c33f927e998b04eccf3958caa25e70e4d537944e446206bbd3 |
IEDL.DBID | ACS |
ISSN | 1043-1802 1520-4812 |
IngestDate | Wed Jul 02 05:08:09 EDT 2025 Mon Jun 30 08:30:21 EDT 2025 Thu Apr 17 08:38:14 EDT 2025 Sun Jul 06 05:07:17 EDT 2025 Thu Apr 17 08:51:30 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Language | English |
License | https://doi.org/10.15223/policy-029 https://doi.org/10.15223/policy-037 https://doi.org/10.15223/policy-045 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-a333t-337bc49414df813c33f927e998b04eccf3958caa25e70e4d537944e446206bbd3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0003-1176-2441 0000-0001-7975-0346 0000-0001-6796-8241 0000-0002-6000-6100 0000-0003-4680-5755 |
PMID | 40176353 |
PQID | 3201557188 |
PQPubID | 45565 |
PageCount | 14 |
ParticipantIDs | proquest_miscellaneous_3185788940 proquest_journals_3201557188 pubmed_primary_40176353 crossref_primary_10_1021_acs_bioconjchem_5c00033 acs_journals_10_1021_acs_bioconjchem_5c00033 |
PublicationCentury | 2000 |
PublicationDate | 2025-04-16 |
PublicationDateYYYYMMDD | 2025-04-16 |
PublicationDate_xml | – month: 04 year: 2025 text: 2025-04-16 day: 16 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Washington |
PublicationTitle | Bioconjugate chemistry |
PublicationTitleAlternate | Bioconjugate Chem |
PublicationYear | 2025 |
Publisher | American Chemical Society |
Publisher_xml | – name: American Chemical Society |
References | ref9/cit9 ref45/cit45 ref3/cit3 ref27/cit27 ref56/cit56 ref16/cit16 Schuhmacher J. (ref55/cit55) 2005; 46 ref52/cit52 ref23/cit23 ref31/cit31 ref2/cit2 Israeli R. S. (ref8/cit8) 1994; 54 ref34/cit34 ref37/cit37 ref20/cit20 ref48/cit48 ref17/cit17 ref10/cit10 ref35/cit35 ref53/cit53 ref19/cit19 ref21/cit21 ref42/cit42 ref46/cit46 ref49/cit49 ref13/cit13 ref24/cit24 ref38/cit38 Markwalder R. (ref4/cit4) 1999; 59 ref54/cit54 ref6/cit6 ref36/cit36 ref18/cit18 Benoiton N. L. (ref50/cit50) 2006 ref11/cit11 ref25/cit25 ref29/cit29 ref32/cit32 ref39/cit39 ref14/cit14 ref5/cit5 ref51/cit51 ref43/cit43 ref28/cit28 Bandari R. P. (ref40/cit40) 2018; 5 ref26/cit26 ref12/cit12 ref15/cit15 ref41/cit41 ref22/cit22 ref33/cit33 ref30/cit30 ref47/cit47 ref1/cit1 ref44/cit44 ref7/cit7 |
References_xml | – ident: ref17/cit17 doi: 10.1002/pros.22789 – ident: ref23/cit23 doi: 10.1021/acsomega.4c00489 – ident: ref11/cit11 doi: 10.1021/jm020515w – ident: ref32/cit32 doi: 10.1021/acsmedchemlett.4c00324 – ident: ref5/cit5 doi: 10.1016/S0090-4295(96)00184-7 – ident: ref45/cit45 doi: 10.1021/jm100729b – ident: ref33/cit33 doi: 10.1097/MNM.0000000000001520 – ident: ref48/cit48 doi: 10.1002/psc.2836 – ident: ref49/cit49 doi: 10.1016/j.jscs.2010.12.006 – ident: ref46/cit46 doi: 10.1021/bc025536j – ident: ref6/cit6 doi: 10.1016/1078-1439(95)00002-Y – ident: ref30/cit30 doi: 10.3390/pharmaceutics11070358 – ident: ref16/cit16 doi: 10.1021/bc200279b – ident: ref22/cit22 doi: 10.3390/cancers13225766 – ident: ref3/cit3 doi: 10.3390/molecules22040523 – ident: ref56/cit56 doi: 10.18632/oncotarget.9004 – ident: ref38/cit38 doi: 10.1021/acs.jmedchem.0c01785 – ident: ref53/cit53 doi: 10.2967/jnumed.109.064444 – ident: ref39/cit39 doi: 10.1016/j.nucmedbio.2014.01.001 – ident: ref27/cit27 doi: 10.1007/s00726-010-0546-y – ident: ref36/cit36 doi: 10.1097/MNM.0000000000000966 – ident: ref41/cit41 doi: 10.3390/pharmaceutics12070614 – ident: ref10/cit10 doi: 10.1016/j.bmc.2004.06.031 – volume: 46 start-page: 691 issue: 4 year: 2005 ident: ref55/cit55 publication-title: J. Nucl. Med. – volume: 54 start-page: 1807 issue: 7 year: 1994 ident: ref8/cit8 publication-title: Cancer Res. – ident: ref9/cit9 doi: 10.1021/jm0001774 – ident: ref47/cit47 doi: 10.1039/c39940002559 – ident: ref51/cit51 doi: 10.1021/bc300659k – ident: ref20/cit20 doi: 10.1021/acs.jmedchem.5b01268 – ident: ref52/cit52 doi: 10.1016/j.molstruc.2021.130127 – ident: ref25/cit25 doi: 10.1021/bc4005377 – ident: ref14/cit14 doi: 10.1021/jm401703a – ident: ref44/cit44 doi: 10.1016/j.bmcl.2019.01.040 – ident: ref13/cit13 doi: 10.1021/jm300488m – ident: ref28/cit28 doi: 10.1016/j.nucmedbio.2021.03.005 – ident: ref34/cit34 doi: 10.1021/acsmedchemlett.3c00057 – volume: 59 start-page: 1152 issue: 5 year: 1999 ident: ref4/cit4 publication-title: Cancer Res. – ident: ref7/cit7 doi: 10.1016/j.humpath.2006.11.012 – ident: ref31/cit31 doi: 10.1021/acs.bioconjchem.5b00687 – ident: ref19/cit19 doi: 10.2967/jnumed.114.147413 – ident: ref37/cit37 doi: 10.3390/pharmaceutics16111358 – ident: ref1/cit1 doi: 10.1016/j.bioorg.2019.103154 – ident: ref2/cit2 doi: 10.3322/caac.21492 – ident: ref12/cit12 doi: 10.1021/jm051019l – ident: ref18/cit18 doi: 10.1021/acs.jmedchem.5b01210 – ident: ref29/cit29 doi: 10.3390/cancers11091371 – ident: ref15/cit15 doi: 10.1021/acs.bioconjchem.5b00679 – ident: ref26/cit26 doi: 10.1002/pros.22784 – ident: ref43/cit43 doi: 10.1021/acsptsci.4c00070 – volume-title: Chemistry of Peptide Synthesis year: 2006 ident: ref50/cit50 – ident: ref54/cit54 doi: 10.1046/j.1525-1411.2001.003001001.x – ident: ref21/cit21 doi: 10.3390/ph16050674 – volume: 5 start-page: 11 issue: 1 year: 2018 ident: ref40/cit40 publication-title: Chem. Biol. Lett. – ident: ref35/cit35 doi: 10.1007/s10967-018-6285-3 – ident: ref24/cit24 doi: 10.1002/jlcr.3749 – ident: ref42/cit42 doi: 10.3390/cancers15020442 |
SSID | ssj0009182 |
Score | 2.4639747 |
Snippet | Heterodimeric approaches have emerged as a promising method for simultaneously targeting multiple receptors on tumor cells using a single molecule.... |
SourceID | proquest pubmed crossref acs |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 748 |
SubjectTerms | Antigens, Surface - metabolism Cell Line, Tumor Chelating agents Chelating Agents - chemistry Chelation Conjugates Diagnostic agents Gastrin Gastrin-releasing peptide Glutamate Carboxypeptidase II - metabolism Heterocyclic Compounds, 1-Ring - chemistry Humans Ligands Male NMR Nuclear magnetic resonance Pharmacology Prostate Prostate cancer Prostatic Neoplasms Radioactive tracers Radiopharmaceuticals - chemical synthesis Radiopharmaceuticals - chemistry Receptors Receptors, Bombesin - metabolism Spectra Stereoselectivity Synthesis Tumor cells |
Title | Choice of an Optimal Modular Strategy for the Synthesis of DOTA-Containing Heterobivalent Agents Targeting PSMA and GRPr |
URI | http://dx.doi.org/10.1021/acs.bioconjchem.5c00033 https://www.ncbi.nlm.nih.gov/pubmed/40176353 https://www.proquest.com/docview/3201557188 https://www.proquest.com/docview/3185788940 |
Volume | 36 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwED-NIcReGGx8FAYYCfFEuvgjifOYFUaFVDatnbS3yHZsUaYmaGklyl_POR_b0DQNnhLFsR3bZ9_vcuefAd5Tqa0LqQsQLNtApMoF0jEXJCFVNHKRccZ7dCff4vGp-HoWnW0AvcWDz-i-MvVQzyu0Dn9gMxbDyHgcz-_BfRYj2PZoaDS94tmlsnVweuZN6YN33t5RkFdLpv5bLd2CNRudc7gNJ_3OnTbU5Hy4Wuqh-X2TyPHfm_MYHnUIlGStyDyBDVvuwG5WovW9WJMPpIkJbX6278CDg_7u4ag_GW4Xfo2-V7i-kMoRVZIjXHQWWOCkKnxIK-n4btcE4TBBeEmm6xIv9bz2GT4dzbLAU2K1J1OQsQ_HqfQcBR7VH8n8Tq-azJr4dJ9-PJ1kWEtBvpwcXzyF08PPs9E46E5wCBTnfBlwnmgjUkFF4STlhnOXssSiiadDgcLjeBpJoxSLbBJaUUQclwdh0URlYax1wZ_BZlmV9gWQNFaJkjqROmYC86XWFDFLTaJF4oyJB_ARuzbvZmCdN851RnP_8Fp_511_DyDsxzv_2fJ63J1lr5eLq2o486ATFbwcwLvLZBwP73dRpa1W-I7n25IyFeEAnrfydFknmreeEpC__L_PfwVbzB9E7Ekn4z3YXF6s7GtER0v9ppkPfwAB9QvE |
linkProvider | American Chemical Society |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED-NITRe-Nj4KAxmJMQTKYntJM5jKIwC6zbRTtqeotixRUFN0NJKlL-euyRtAQlN8JQojr8vvt_lzj8DPA-Uts4PnIdg2XoyyZ2nHHde7Ad5ELrQOEMe3dFxNDyTH87D8y1Qq70w2IgaS6obJ_6GXSB4Rc_0tEIj8Qv2ZtYPDcF5cQ2uIyThFMyXDsYbut1AtX5OIuBUFMNzcEVBpJ1M_bt2-gvkbFTP4W24WDe6iTj52l_Mdd_8-IPP8X96dQdudXiUpa0A3YUtW-7CXlqiLT5bshesiRBtfr3vwo3Xq7udweqcuD34Pvhc4WrDKsfykp3gEjTDAkdVQQGurGO_XTIExwzBJhsvS7zU05oyvDmZpB4RZLXnVLAhBedUeorij8qQpbTvq2aTJlqd0k_HoxRrKdi7T6eX9-Ds8O1kMPS68xy8XAgx94SItZGJDGThVCCMEC7hsUWDT_sSRcmJJFQmz3loY9_KIhS4WEiLBiv3I60LcR-2y6q0D4ElUR7nSsdKR1xivsSaIuKJibWMnTFRD17i0Gbd91hnjaudBxk9_GW8s268e-Cvpj371rJ8XJ1lfyUem2oEJwiK6l714Nk6GeeDvDB5aasFvkPsW0ol0u_Bg1as1nWisUsEgeLRvzX_AHaGk9FRdvT--ONjuMnpiGKio4z2YXt-ubBPEDfN9dPmE_kJNRkUJQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3rb9MwED-NIR5feGw8CoMZCfGJlCR2EkfiS-go5dGtop20L1MUO7YoqMm0tBLlr-cujw6Q0ASfEtnx--y7y51_B_Dck8pY17MOCsvGEXFmHWl960Sul3mBDbTVZNEdH4ajY_HhJDjZgtfdXRjsRIU1VbURn3b1WW5bhAHvFaWreYmK4lcc0aIfaBLp-RW4SsY7cuhLBtMLyF1PNrZOAuGU5Mezf0lFxKF09TuH-ovYWbOf4W043XS89jr51l8tVV__-APT8X9HdgdutXIpSxpCugtbptiB3aRAnXyxZi9Y7Sla_4LfgWtvurcbgy5e3C58H3wp8dRhpWVZwY7wKFpgheMyJ0dX1qLgrhkKyQyFTjZdF_io5hUVODiaJQ4BZTXxKtiInHRKNcdtgEyRJXT_q2Kz2mud8ifTcYKt5Ozd58n5PTgevp0NRk4b18HJOOdLh_NIaRELT-RWelxzbmM_Mqj4KVcgSVkeB1JnmR-YyDUiDzgeGsKg4uq7oVI5vw_bRVmYh8DiMIsyqSKpQl9gudjoPPRjHSkRWa3DHrzEqU3bfVmltcnd91JK_GW-03a-e-B2S5-eNWgflxfZ60jkohnukyiKbF_24NkmG9eDrDFZYcoVfkMoXFLGwu3Bg4a0Nm2i0ktAgfzRv3V_H65PDobpp_eHHx_DTZ8iFRMqZbgH28vzlXmC4tNSPa13yU8Suhao |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Choice+of+an+Optimal+Modular+Strategy+for+the+Synthesis+of+DOTA-Containing+Heterobivalent+Agents+Targeting+PSMA+and+GRPr&rft.jtitle=Bioconjugate+chemistry&rft.au=Petrov%2C+Stanislav+A.&rft.au=Grigoriev%2C+Gleb+P.&rft.au=Orlov%2C+Grigory+A.&rft.au=Zyk%2C+Nikolay+Y.&rft.date=2025-04-16&rft.pub=American+Chemical+Society&rft.issn=1043-1802&rft.eissn=1520-4812&rft.volume=36&rft.issue=4&rft.spage=748&rft.epage=761&rft_id=info:doi/10.1021%2Facs.bioconjchem.5c00033&rft.externalDocID=e96468030 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1043-1802&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1043-1802&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1043-1802&client=summon |